

## Vision


---

To become the leader in developing and commercializing innovative therapies based on our proprietary sindbis vector.

## Our Mission

---

Exploit the cancer killing ability of the sindbis oncolytic viral vector, and fight every day for cancer patients, their doctors, nurses and caregivers, to find a cure for cancer.



Sindbis Virus

## Corporate Overview

---

- Cynvec is a privately held biotech company created in 2004 with technology licensed from New York University Medical Center.
- Cynvec is developing proprietary therapeutics and cancer diagnostics based on the use of the sindbis oncolytic virus, which has been shown to selectively bind to, and kill, a number of cancer cell types via the over expressed laminin receptor, without affecting normal cells.
- The company holds an exclusive worldwide license related to the use of the sindbis viral vector and currently has a solid proprietary base with issued composition of matter patents for CYN 101, its lead product candidate.
- Cynvec has a virtual business model with no fixed costs and less than five employees. The company has raised \$10 million to date.

## CYN 101

---

Cynvec's lead product candidate, CYN 101, is a genetically engineered cell-killing (apoptotic) form of a naturally occurring virus targeting the laminin receptor, which is over-expressed on the surface of many solid tumors. In pre-clinical models of ovarian and pancreatic cancer, CYN 101 has shown tumor eradication and highly significant survival rates as both a single agent and in combination with licensed chemotherapies. CYN 101 is currently in late-stage preclinical testing, with Phase I clinical trials scheduled to start Q3 2009.

## CYN 101 Advantages

---


- **Cancer targeting** – targets cancer cells via laminin receptor
- **Naturally apoptotic** – base vector kills cancer cells without any inserts or payloads
- **Non immunogenic** – no neutralizing antibodies seen to date
- **Replication defective** – engineered to infect only once (minimizes risk vs replication competent vectors)
- **RNA genome** – no risk of insertional mutagenesis, not gene therapy, no five-year follow up
- **Ability to re-target** – monoclonal antibodies (protein A); single chain antibodies; other peptides and ligands
- **Payload delivery** – can be engineered to include therapeutic payload: TK, interferons, interleukins, SiRNAs, and others

## Product Pipeline

The sindbis viral vector is a unique platform technology, allowing for numerous therapeutic and diagnostic applications. Beyond CYN 101, Cynvec is conducting research into:

- Expanding the utility of the base vector by attaching retargeting molecules, inserting therapeutic payloads and diagnostic markers.
- Developing a companion vector to be used as a cancer diagnostic tool.
- Conducting a screening program to identify small molecules that bind to the laminin receptor and may be implicated in Alzheimer's disease, multiple sclerosis and Parkinson's.

## Targeting Areas of Significant Unmet Medical Need



## Management Team

Frank Stonebanks, CEO  
Richard Purcell, COO

## Board of Directors

Steve Blumenthal  
Leonard Litwin  
Robert Ivanhoe  
George Vergis, PhD, MBA

Frank Stonebanks  
Richard Purcell

## Scientific Advisory Board

Dr. Daniel Meruelo, New York University  
Dr. David Sidransky, Johns Hopkins University  
Dr. Herman Yee, New York University

Dr. Steve Larsen, Memorial Sloan-Kettering  
Dr. Yuman Fong, Memorial Sloan-Kettering  
Dr. Judith Wolf, M.D. Anderson Cancer Center

## Contacts

Frank Stonebanks  
CEO  
212.672.1708

Rhonda Chiger  
Investor Relations  
917.322.2569

Chris Smith  
Media Relations  
973.442.1555

**Cynvec LLC**  
245 Park Ave., 39th Floor  
New York, NY 10167  
[www.cynvec.com](http://www.cynvec.com)